Obesity Abstracts

Background: Obesity is an important predictor for development of obstructive sleep apnoea (OSA). Patients undergoing bariatric surgery are at increased risk of peri-operative morbidity from undiagnosed OSA. We aim to assess the prevalence and severity of OSA, and its association with the Epworth Screening Scale (ESS) in a bariatric surgical population.Methods: Retrospective study of adult patients who attended the Tier 4 Medical Obesity Clinic (MOC) at G...

Introduction: Post-bariatric surgery hypoglycaemia (BPH) is a metabolic complication of bariatric surgery, which may develop months or years post-procedure and is encountered increasingly frequently in obesity medicine. We present a case series from our large Tier 4 service, illustrating the challenges posed when diagnosing and managing this condition.Case 1: 51F with a history of obesity (BMI 55, weight 159kg) and Roux-...

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...